A detailed history of Bank Of Montreal transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Bank Of Montreal holds 68,562 shares of BPMC stock, worth $6.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
68,562
Previous 69,040 0.69%
Holding current value
$6.2 Million
Previous $7.44 Million 14.81%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$84.1 - $120.5 $40,199 - $57,599
-478 Reduced 0.69%
68,562 $6.34 Million
Q2 2024

Aug 14, 2024

BUY
$85.18 - $108.78 $5.88 Million - $7.51 Million
69,040 New
69,040 $7.44 Million
Q2 2023

Aug 02, 2023

BUY
$42.2 - $66.37 $278,731 - $438,373
6,605 New
6,605 $417,000
Q1 2022

May 12, 2022

SELL
$54.1 - $110.08 $1.19 Million - $2.42 Million
-22,008 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$94.25 - $115.99 $2.07 Million - $2.55 Million
22,008 New
22,008 $2.45 Million

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.4B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Bank Of Montreal Portfolio

Follow Bank Of Montreal and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.